AU2001227930A1 - Clostridial toxin derivatives and methods for treating pain - Google Patents
Clostridial toxin derivatives and methods for treating painInfo
- Publication number
- AU2001227930A1 AU2001227930A1 AU2001227930A AU2793001A AU2001227930A1 AU 2001227930 A1 AU2001227930 A1 AU 2001227930A1 AU 2001227930 A AU2001227930 A AU 2001227930A AU 2793001 A AU2793001 A AU 2793001A AU 2001227930 A1 AU2001227930 A1 AU 2001227930A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- clostridial toxin
- treating pain
- toxin derivatives
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09489667 | 2000-01-19 | ||
US09/489,667 US7138127B1 (en) | 2000-01-19 | 2000-01-19 | Clostridial toxin derivatives and methods for treating pain |
PCT/US2001/001529 WO2001053336A1 (en) | 2000-01-19 | 2001-01-17 | Clostridial toxin derivatives and methods for treating pain |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001227930A1 true AU2001227930A1 (en) | 2001-07-31 |
Family
ID=23944774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001227930A Abandoned AU2001227930A1 (en) | 2000-01-19 | 2001-01-17 | Clostridial toxin derivatives and methods for treating pain |
Country Status (4)
Country | Link |
---|---|
US (13) | US7138127B1 (en) |
AR (1) | AR027234A1 (en) |
AU (1) | AU2001227930A1 (en) |
WO (1) | WO2001053336A1 (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7227010B2 (en) * | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
KR100876060B1 (en) | 1999-08-25 | 2008-12-26 | 알러간, 인코포레이티드 | Activatable Recombinant Neurotoxins |
WO2001047512A2 (en) * | 1999-12-08 | 2001-07-05 | Fluoro Probe, Inc. | Method for relieving pain associated with an internal disease site |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
DE10019157A1 (en) * | 2000-04-18 | 2001-11-15 | Stefan Duebel | Method for introducing ligands into living cells |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
AU2003259246A1 (en) * | 2002-07-29 | 2004-02-16 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1740198A4 (en) * | 2004-04-26 | 2009-03-04 | Immuneregen Biosciences Inc | Anti-aging effects of substance p |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
DE102004043009A1 (en) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transport protein for introducing chemical compounds into nerve cells |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
WO2006101809A1 (en) * | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
DE102005019302A1 (en) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier for targeting nerve cells |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
JP2009543557A (en) * | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | Modified clostridial toxin with enhanced translocation ability and altered targeting activity against clostridial toxin target cells |
EP2505592A1 (en) | 2006-07-11 | 2012-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
RU2491086C2 (en) * | 2007-10-23 | 2013-08-27 | Аллерган, Инк. | Method of treating urinogenital neurological disorders with using modified clostridial toxins |
JP2011514307A (en) * | 2007-10-23 | 2011-05-06 | アラーガン、インコーポレイテッド | Method of treating chronic neurogenic inflammation using modified Clostridial toxin |
US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
BRPI0915142A8 (en) | 2008-06-12 | 2018-01-02 | Syntaxin Ltd | POLYPEPTIDES, NUCLEIC ACID AND USES THEREOF |
US9478108B2 (en) * | 2008-11-10 | 2016-10-25 | Archangel Device Llc | Multi-directional, multi-functional, wearable safety lighting apparatus |
US8455203B2 (en) | 2009-03-13 | 2013-06-04 | Allergan, Inc. | Immuno-based retargeted endopeptidase activity assays |
US20100303794A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases |
US20100303788A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases |
US20100303789A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases |
US20100303798A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases |
US20100303783A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases |
US20100303791A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
EP2483666A1 (en) | 2009-10-02 | 2012-08-08 | Allergan, Inc. | In vitro method of determining changes in a protein environment |
RU2569185C2 (en) | 2010-01-25 | 2015-11-20 | Аллерган, Инк. | Method for intracellular conversion of single-stranded proteins into their double-stranded form |
JP6148979B2 (en) | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドAllergan,Incorporated | Degradable clostridial toxin |
US20130330369A1 (en) | 2010-10-08 | 2013-12-12 | Allergan, Inc. | Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof |
EP2627350A1 (en) | 2010-10-14 | 2013-08-21 | Allergan, Inc. | Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
EP2672958A1 (en) | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
WO2012174123A1 (en) | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
US20130171122A1 (en) | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
EP2934571B1 (en) | 2012-12-18 | 2018-05-30 | Allergan, Inc. | Prophylactic treatment of herpes recurrence |
US9447405B2 (en) | 2013-03-08 | 2016-09-20 | Wisconsin Alumni Research Foundation | Regulation of specific spinal neurons regulating pain transmission via chimeric toxins |
US10501589B2 (en) | 2013-09-12 | 2019-12-10 | Northeastern University | Nanostructured bacteria-resistant polymer materials |
CA2969463A1 (en) * | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
BR112018073388A2 (en) * | 2016-05-13 | 2019-07-02 | Delnova Inc | treatment of chemodenervation side effects |
TW201814045A (en) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | Method for producing di-chain clostridial neurotoxins |
CN109790204A (en) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | Heterozygosis neurotoxin |
EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
JP2022546517A (en) * | 2019-08-30 | 2022-11-04 | イーオン バイオファーマ インコーポレイテッド | Neurotoxin composition for use in treating headache |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US466244A (en) * | 1891-12-29 | kelly | ||
US4189426A (en) | 1976-04-12 | 1980-02-19 | Hoffmann-La Roche, Inc. | Recombinant hormonal compositions and method |
US4481139A (en) * | 1983-04-13 | 1984-11-06 | Board Of Regents, The University Of Texas System | Peptide antagonists of substance P |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
JPS60248659A (en) | 1984-05-25 | 1985-12-09 | Microbial Chem Res Found | 3(n-(mercaptoacyl))amino-4-arylbutyric acid derivative and analgesic containing said derivative as active component |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5410019A (en) * | 1987-09-24 | 1995-04-25 | The Administrators Of The Tulane-Educational Fund | Therapeutic peptides |
EP0499990B1 (en) | 1991-02-19 | 1996-05-15 | Takeda Chemical Industries, Ltd. | Method for producing cysteine-free peptides |
EP0823486A3 (en) | 1991-06-27 | 2004-02-11 | Genelabs Technologies, Inc. | Method for inhibiting the binding of a dna-binding protein to duplex dna |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
US5891842A (en) | 1993-04-09 | 1999-04-06 | Trustees Of Tufts College | Methodology for eliciting an analgesic response in a living subject |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
JP3122319B2 (en) | 1994-05-02 | 2001-01-09 | アソシエーティド ユニバーシティーズ,インコーポレイティド | Tin-117m-containing radiotherapeutic agent |
JP3066079B2 (en) | 1994-05-09 | 2000-07-17 | ビンダー,ウィリアム,ジェイ. | How to reduce headaches |
US6203794B1 (en) | 1994-05-31 | 2001-03-20 | Allergan Sales, Inc. | Modification of clostridial toxins for use as transport proteins |
US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
US5846216A (en) | 1995-04-06 | 1998-12-08 | G & P Technologies, Inc. | Mucous membrane infusor and method of use for dispensing medications |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
WO1998001754A1 (en) | 1996-07-08 | 1998-01-15 | University Of Massachusetts Dartmouth | Novel proteins within the type e botulinum neurotoxin complex |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US5955368A (en) * | 1998-04-06 | 1999-09-21 | Wisconsin Alumni Research Foundation | Expression system for clostridium species |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
KR100876060B1 (en) * | 1999-08-25 | 2008-12-26 | 알러간, 인코포레이티드 | Activatable Recombinant Neurotoxins |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
US6641820B1 (en) * | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6500436B2 (en) * | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
TW540386U (en) * | 2002-07-02 | 2003-07-01 | Lu-Rung Liau | Device for massaging human body |
GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
DE102004043009A1 (en) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transport protein for introducing chemical compounds into nerve cells |
EP1830872B1 (en) | 2004-12-01 | 2010-11-17 | Health Protection Agency | Fusion proteins |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
WO2006101809A1 (en) * | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
-
2000
- 2000-01-19 US US09/489,667 patent/US7138127B1/en not_active Expired - Lifetime
-
2001
- 2001-01-17 WO PCT/US2001/001529 patent/WO2001053336A1/en active Application Filing
- 2001-01-17 AR ARP010100202A patent/AR027234A1/en unknown
- 2001-01-17 AU AU2001227930A patent/AU2001227930A1/en not_active Abandoned
- 2001-08-23 US US09/938,112 patent/US7056729B2/en not_active Expired - Fee Related
-
2005
- 2005-11-03 US US11/265,953 patent/US7244436B2/en not_active Expired - Lifetime
- 2005-11-03 US US11/265,988 patent/US7244437B2/en not_active Expired - Lifetime
- 2005-11-03 US US11/265,823 patent/US7262291B2/en not_active Expired - Lifetime
-
2006
- 2006-08-22 US US11/466,244 patent/US7413742B2/en not_active Expired - Fee Related
-
2007
- 2007-06-20 US US11/765,863 patent/US7425338B2/en not_active Expired - Fee Related
- 2007-06-20 US US11/765,878 patent/US7622127B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/924,880 patent/US7736659B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/924,933 patent/US7833535B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 US US12/175,288 patent/US7704512B2/en not_active Expired - Fee Related
- 2008-07-18 US US12/175,621 patent/US8017131B2/en not_active Expired - Fee Related
- 2008-09-16 US US12/211,594 patent/US7780968B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20060067929A1 (en) | 2006-03-30 |
US7138127B1 (en) | 2006-11-21 |
US7056729B2 (en) | 2006-06-06 |
US7622127B2 (en) | 2009-11-24 |
US20080317782A1 (en) | 2008-12-25 |
US7244437B2 (en) | 2007-07-17 |
US20070110769A1 (en) | 2007-05-17 |
US7780968B2 (en) | 2010-08-24 |
US20060093625A1 (en) | 2006-05-04 |
US20080213311A1 (en) | 2008-09-04 |
US20080095872A1 (en) | 2008-04-24 |
US7413742B2 (en) | 2008-08-19 |
US7425338B2 (en) | 2008-09-16 |
US8017131B2 (en) | 2011-09-13 |
US20090010967A1 (en) | 2009-01-08 |
US7244436B2 (en) | 2007-07-17 |
US7704512B2 (en) | 2010-04-27 |
US7736659B2 (en) | 2010-06-15 |
US20020068699A1 (en) | 2002-06-06 |
WO2001053336A1 (en) | 2001-07-26 |
US7262291B2 (en) | 2007-08-28 |
US20060222666A1 (en) | 2006-10-05 |
US7833535B2 (en) | 2010-11-16 |
AR027234A1 (en) | 2003-03-19 |
US20070259003A1 (en) | 2007-11-08 |
US20080317783A1 (en) | 2008-12-25 |
US20090042799A1 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001227930A1 (en) | Clostridial toxin derivatives and methods for treating pain | |
AU2001273406A1 (en) | Clostridial toxin derivatives and methods for treating pain | |
AU2001265043A1 (en) | Botulinum toxin implant | |
AU2001286419A1 (en) | Endourethral device and method | |
AU2001234565A1 (en) | System and method for user authentication | |
AU2001292836A1 (en) | Endoscopic targeting method and system | |
AU2001238169A1 (en) | Needleless access apparatus and system | |
AU3309300A (en) | Hair treatment device and method | |
AU2001268564A1 (en) | Alpha-glycosylceramides for treating bacterial and fungal infections | |
AU2001237997A1 (en) | Method and system for event-centric user profiling and targeting | |
AU2001232647A1 (en) | Methods and devices for treating stuttering problems | |
AU5381399A (en) | Hair treatment device and method | |
AU2271400A (en) | Composition, kit, method and device for hair treatment | |
AU2001265967A1 (en) | Cryptographic method and cryptographic device | |
AU2001214905A1 (en) | Security device and method | |
AU2001279850A1 (en) | Method and arrangement for studsystem | |
AU5838700A (en) | Method for treating and preventing finger disorders | |
AU2001275127A1 (en) | Method for treating alcohol intoxication and alcohol abuse | |
AU2001236601A1 (en) | Methods and devices for remediation and fermentation | |
AU2002228663A1 (en) | Microorganism neutralization device and method | |
AU2001229471A1 (en) | Apparatus and method for hair treatment | |
AU2001218024A1 (en) | Methods for treating and preventing alopecia | |
AU1923501A (en) | Pyridinones to treat and prevent bacterial infections | |
AU2002211359A1 (en) | Stem cell-based methods for preventing and treating tumor | |
AU2001292952A1 (en) | Selective inactivation and copy-protection |